在新的多发性硬化症时代,克拉德里宾片
Fabio Buttari1,2, Ettore Dolcetti2,3, Francesca Romana Rizzo4
1Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Therapeutic advances in neurological disorders
|June 23, 2025
概括
克拉迪片 (CladT) 通过选择性调节免疫系统,为治疗多发性硬化症 (MS) 提供了一种新的方法. 这种疗法有效地减少了MS患者的神经损伤和残疾进展.
科学领域:
- 神经免疫学 神经免疫学
- 临床治疗学 临床治疗学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫性疾病,导致中枢神经系统 (CNS) 脱髓化和不可逆转的神经损伤.
- 目前的疾病修饰疗法 (DMT) 旨在治疗多发性硬化症,但需要取得进展才能持续有效并改善安全性.
研究的目的:
- 审查克拉迪宾片 (CladT) 在治疗多发性硬化症中的治疗潜力和临床疗效.
- 检查CladT的免疫复合机制,中枢神经系统的影响,以及对长期结果和生活质量的影响.
主要方法:
- 临床试验和实践研究对MS治疗的克拉德里宾片进行系统审查.
- 分析CladT对免疫细胞,中枢神经系统标记物,病变活性和患者报告结果的影响.
主要成果:
- CladT选择性地向淋巴细胞,从而导致持续的免疫调节,并保持先天免疫和免疫球蛋白水平.
- 克拉德降低了MS复发率,残疾进展和MRI检测到的疾病活动,包括活跃和缓慢扩张的病变.
- 有证据表明,CladT穿透了血脑屏障,减少了CSF免疫标记物,如橄克隆带和神经纤维光链.
结论:
- 克拉德里宾片代表了MS治疗的重大进步,提供了高效率和有利的安全性.
- 早期,高效的CladT治疗对于优化长期结果和减少活跃多发性硬化症患者残疾累积至关重要.
- 新兴的生物标志物可能使个性化治疗策略成为可能,进一步增强CladT在不断变化的MS治疗领域中的作用.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:29Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:29Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204